Since the TME is dominated by tumor-associated macrophages (called microglia) and regulatory T cells, cytokine-based therapies targeting CSF1R, TGF-β, IDO1, and VEGF signaling are under evaluation for their contribution to clinical efficacy [34]. This evidence concerns the gene TGFB1 and neoplasm.